Jonathan Graff-Radford

List of Publications by Year
in descending order

207	8,477	41258	66788
papers	citations	49 h-index	78 g-index

208	208	208	8606
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
2	Cascading network failure across the Alzheimerâ€™s disease spectrum. Brain, 2016, 139, 547-562.	3.7	401
3	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	3.7	309
4	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	3.8	223
5	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
6	New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurology, The, 2021, 20, 222-234.	4.9	214
7	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Agingâ€“Alzheimerâ€™s Association Research Framework. JAMA Neurology, 2019, 76, 1174.	4.5	182
8	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162
9	AVâ€‘1451 tau and Î²â€‘amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
10	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
11	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Annals of Neurology, 2017, 82, 706-718.	2.8	136
12	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129
13	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	3.7	126
14	Vascular Imaging Abnormalities and Cognition. Stroke, 2015, 46, 433-440.	1.0	125
15	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	4.5	114
16	Performance of plasma phosphorylated tau 181 and 217 in the community. Nature Medicine, 2022, 28, 1398-1405.	15.2	114
17	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
18	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology, 2017, 74, 718.	4.5	107

#	Article	IF	Citations
19	Clinical and Radiologic Correlations of Central Pontine Myelinolysis Syndrome. Mayo Clinic Proceedings, 2011, 86, 1063-1067.	1.4	95
20	Preeclampsia and cognitive impairment later in life. American Journal of Obstetrics and Gynecology, 2017, 217, 74.e1-74.e11.	0.7	93
21	¹⁸F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. Journal of Nuclear Medicine, 2017, 58, 632-638.	2.8	91
22	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's and Dementia, 2022, 18, 1128-1140.	0.4	88
23	The neuroanatomy of pure apraxia of speech in stroke. Brain and Language, 2014, 129, 43-46.	0.8	83
24	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	4.5	81
25	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81
26	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
27	The alien limb phenomenon. Journal of Neurology, 2013, 260, 1880-1888.	1.8	75
28	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
29	Cerebral Amyloid Angiopathy. Journal of the American College of Cardiology, 2017, 70, 1173-1182.	1.2	73
30	[¹⁸F]AVâ€‘1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	2.8	73
31	Cognitive dysfunction in atrial fibrillation. Nature Reviews Cardiology, 2018, 15, 744-756.	6.1	73
32	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	3.7	72
33	Neuroimaging and clinical features in type II (late-onset) Alexander disease. Neurology, 2014, 82, 49-56.	1.5	71
34	The limbic and neocortical contribution of Î±â€synuclein, tau, and amyloid Î² to disease duration in dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 330-339.	0.4	69
35	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
36	Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism. JAMA Neurology, 2017, 74, 839.	4.5	68

#	Article	IF	Citations
37	Artificial Intelligenceâ€“Electrocardiography to Predict Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009355.	2.1	68
38	[¹⁸F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
39	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
40	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
41	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain, 2012, 135, 2470-2477.	3.7	64
42	Neuroimaging Correlates of Cerebral Microbleeds. Stroke, 2017, 48, 2964-2972.	1.0	63
43	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
44	Caudate nucleus as a component of networks controlling behavior. Neurology, 2017, 89, 2192-2197.	1.5	62
45	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
46	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
47	Magnetic resonance spectroscopy in Alzheimer’s disease. Neuropsychiatric Disease and Treatment, 2013, 9, 687.	1.0	61
48	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
49	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.4	58
50	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.5	55
51	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	1.4	54
52	Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. Mayo Clinic Proceedings, 2018, 93, 145-154.	1.4	53
53	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Human Brain Mapping, 2019, 40, 1618-1631.	1.9	53
54	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.5	53

#	Article	IF	Citations
55	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
56	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
57	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	2.8	49
58	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
59	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47
60	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1713-1724.	1.2	45
61	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 1693-1706.	1.6	44
62	Executive Dysfunction and the Prefrontal Cortex. CONTINUUM Lifelong Learning in Neurology, 2021, 27, 1586-1601.	0.4	44
63	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
64	Association of Apolipoprotein E É›4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. JAMA Network Open, 2019, 2, e1913909.	2.8	41
65	Mediodorsal nucleus and its multiple cognitive functions. Neurology, 2016, 87, 2161-2168.	1.5	40
66	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	1.0	40
67	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. Annals of Neurology, 2019, 86, 866-877.	2.8	40
68	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	1.0	39
69	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€tau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.4	38
70	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
71	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Communications, 2021, 3, fcab106.	1.5	38
72	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 675-685.	0.4	36

#	Article	IF	Citations
73	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. Mayo Clinic Proceedings, 2019, 94, 1516-1523.	1.4	35
74	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
75	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
76	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimer's Research and Therapy, 2021, 13, 199.	3.0	32
77	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31
78	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.5	31
79	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	2.8	31
80	Parkinsonian motor features distinguish the agrammatic from logopenic variant of primary progressive aphasia. Parkinsonism and Related Disorders, 2012, 18, 890-892.	1.1	30
81	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
82	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	1.4	30
83	Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12291.	1.2	30
84	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
85	A robust biomarker of largeâ€scale network failure in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 152-161.	1.2	29
86	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	1.4	29
87	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27
88	The clinical relevance of cerebral microbleeds in patients with cerebral ischemia and atrial fibrillation. Journal of Neurology, 2016, 263, 238-244.	1.8	27
89	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
90	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. Neurobiology of Aging, 2020, 96, 176-183.	1.5	27

#	Article	IF	Citations
91	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
92	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
93	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
94	Population-Based Evaluation of Lumbar Puncture Opening Pressures. Frontiers in Neurology, 2019, 10, 899.	1.1	25
95	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	1.7	25
96	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.5	24
97	Statins and Brain Health: Alzheimerâ€™s Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352.	1.2	23
98	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
99	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
100	Dopamine agonists and Othelloâ€™s syndrome. Parkinsonism and Related Disorders, 2010, 16, 680-682.	1.1	21
101	Progressive Multifocal Leukoencephalopathy in a Patient Treated With Etanercept. Neurologist, 2012, 18, 85-87.	0.4	21
102	Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia. JAMA Neurology, 2016, 73, 123.	4.5	21
103	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	1.5	21
104	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. Annals of Neurology, 2021, 89, 520-533.	2.8	21
105	Batch enrollment for an artificial intelligence-guided intervention to lower neurologic events in patients with undiagnosed atrial fibrillation: rationale and design of a digital clinical trial. American Heart Journal, 2021, 239, 73-79.	1.2	21
106	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer's and Dementia, 2022, 18, 602-611.	0.4	20
107	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.5	19
108	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.5	19

#	Article	IF	Citations
109	Artificial Intelligence-Enabled ECG to Identify Silent Atrial Fibrillation in Embolic Stroke of Unknown Source. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105998.	0.7	19
110	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19
111	Primary Progressive Aphasia and Transient Global Amnesia. Archives of Neurology, 2012, 69, 401.	4.9	18
112	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimerâ€™s pathophysiology. Acta Neuropathologica Communications, 2021, 9, 48.	2.4	18
113	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.4	18
114	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
115	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
116	Transient Epileptic Amnesia: A Treatable Cause of Spells Associated With Persistent Cognitive Symptoms. Frontiers in Neurology, 2019, 10, 939.	1.1	17
117	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
118	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
119	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17
120	Transient Amnesia After Coiling of a Posterior Circulation Aneurysm. Neurocritical Care, 2013, 18, 245-247.	1.2	16
121	Structured handoff checklists improve clinical measures in patients discharged from the neurointensive care unit. Neurology: Clinical Practice, 2015, 5, 42-49.	0.8	16
122	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
123	Cerebral amyloid angiopathy and implications for atrial fibrillation management. Lancet, The, 2017, 390, 9-11.	6.3	16
124	Cognitive Impairment in Patients with Stroke. Seminars in Neurology, 2021, 41, 075-084.	0.5	16
125	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. Neurology, 2017, 89, 2039-2048.	1.5	15
126	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15

#	Article	IF	Citations
127	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	2.1	15
128	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
129	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
130	Automated Hippocampal Subfield Volumetric Analyses in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 78, 927-937.	1.2	14
131	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
132	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
133	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. British Journal of Anaesthesia, 2019, 123, 808-817.	1.5	13
134	Utility of HAS-BLED and CHA2DS2-VASc Scores Among Patients With Atrial Fibrillation and Imaging Evidence of Cerebral Amyloid Angiopathy. Mayo Clinic Proceedings, 2020, 95, 2090-2098.	1.4	13
135	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
136	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. Brain Communications, 2021, 3, fcab076.	1.5	13
137	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
138	Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition. Brain Communications, 2020, 2, fcaa159.	1.5	12
139	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12
140	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	1.5	12
141	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. Neurology, 2022, 98, .	1.5	12
142	Network Localization of Alien Limb in Patients with Corticobasal Syndrome. Annals of Neurology, 2020, 88, 1118-1131.	2.8	11
143	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11
144	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	1.5	11

#	Article	IF	Citations
145	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. Brain Communications, 2021, 3, fcaa238.	1.5	11
146	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
147	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. Acta Neuropathologica, 2022, 144, 1117-1125.	3.9	11
148	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
149	Predictors of adverse outcomes and cost after surgical management for idiopathic normal pressure hydrocephalus: Analyses from a national database. Clinical Neurology and Neurosurgery, 2020, 197, 106178.	0.6	10
150	Prevalence and Trends in Management of Idiopathic Normal Pressure Hydrocephalus in the United States: Insights from the National Inpatient Sample. World Neurosurgery, 2021, 145, e38-e52.	0.7	10
151	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
152	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. Journal of Neuroimaging, 2019, 29, 624-629.	1.0	9
153	CSF1R mutation presenting as dementia with Lewy bodies. Neurocase, 2019, 25, 17-20.	0.2	9
154	Screening and management of atrial fibrillation in primary care. BMJ, The, 2021, 373, n379.	3.0	9
155	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	1.0	9
156	Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis. Journal of Neurology, 2022, 269, 1427-1438.	1.8	9
157	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. NeuroImage, 2022, 251, 119020.	2.1	9
158	Focal brain atrophy in gastric bypass patients with cognitive complaints. Journal of Clinical Neuroscience, 2011, 18, 1671-1676.	0.8	8
159	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volumeâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2431-2436.	1.1	8
160	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
161	Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign. Journal of Alzheimer's Disease, 2022, 86, 491-498.	1.2	8
162	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7

#	Article	IF	Citations
163	Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	1.2	7
164	Expanded genetic insight and clinical experience of DNMT1-complex disorder. Neurology: Genetics, 2020, 6, e456.	0.9	7
165	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2785-2793.	1.1	7
166	Our Efforts in Understanding Normal Pressure Hydrocephalus: Learning from the 100 Most Cited Articles by Bibliometric Analysis. World Neurosurgery, 2020, 137, 429-434.e13.	0.7	7
167	Functional outcome after critical illness in older patients: a population-based study. Neurological Research, 2021, 43, 103-109.	0.6	7
168	Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. Neurology, 2021, 97, 908-909.	1.5	7
169	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	1.5	7
170	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	1.8	7
171	Posterior cortical atrophy: Primary occipital variant. European Journal of Neurology, 2022, 29, 2138-2143.	1.7	7
172	PET Imaging of Dementia. Clinical Nuclear Medicine, 2022, 47, 763-773.	0.7	7
173	History of Hollenhorst Plaques. Stroke, 2015, 46, e82-4.	1.0	6
174	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. Neurocase, 2020, 26, 259-263.	0.2	6
175	High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus. Clinical Neurology and Neurosurgery, 2020, 197, 106099.	0.6	6
176	Artificial Intelligenceâ€“Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	1.4	6
177	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	1.4	5
178	High Mortality Rates Among Patients With Nonâ€Traumatic Intracerebral Hemorrhage and Atrial Fibrillation on Antithrombotic Therapy Are Independent of the Presence of Cerebral Amyloid Angiopathy: Insights From a Populationâ€Based Study. Journal of the American Heart Association, 2020, 9, e016893.	1.6	5
179	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. NeuroImage: Clinical, 2020, 28, 102481.	1.4	5
180	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. Frontiers in Neurology, 2021, 12, 615024.	1.1	5

#	Article	IF	Citations
181	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. Journal of Neurology, 2021, 268, 4752-4758.	1.8	5
182	Population-Based Prevalence of Infarctions on 3D Fluid-Attenuated Inversion Recovery (FLAIR) Imaging. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106583.	0.7	5
183	A Neurological Complication of a Uterine Fibroid. Neurocritical Care, 2013, 18, 93-95.	1.2	4
184	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	0.9	4
185	Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in PRNP: the next generation. Neurocase, 2020, 26, 211-219.	0.2	4
186	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
187	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphereâ€“Predominant Logopenic Progressive Aphasia. Neurology, 2021, 97, e523-e534.	1.5	4
188	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
189	Extramedullary tumors and leukemia. Neurology, 2012, 79, 85-91.	1.5	3
190	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	2.1	3
191	Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 81, 533-543.	1.2	3
192	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583.	3.9	3
193	Fluorodeoxyglucose F18 PET in progressive emotional dysprosody. Neurology, 2012, 79, 480-481.	1.5	2
194	Limb immobilization and corticobasal syndrome. Parkinsonism and Related Disorders, 2012, 18, 1097-1099.	1.1	2
195	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2021, , .	1.2	2
196	Polygenic Scores of Alzheimerâ€™s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. Journal of Alzheimer's Disease, 2022, 88, 1615-1625.	1.2	2
197	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104451.	0.7	1
198	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12269.	1.2	1

#	Article	IF	Citations
199	Fluorodeoxyglucose F18 positron emission tomography in a case of slowly progressive pure alexia. Neurocase, 2014, 20, 476-479.	0.2	0
200	P2â€201: Pathologic Predictors of Disease Duration in Lewy Body Disease. Alzheimer's and Dementia, 2016, 12, P698.	0.4	0
201	[O4â€“04â€“05]: CEREBRAL MICROBLEEDS AND AMYLOID BURDEN: THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2017, 13, P1237.	0.4	0
202	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. Journal of Human Hypertension, 2018, 32, 385-385.	1.0	0
203	Response to â€œLetter to the editor concerning "High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus" by Naylor et al. (Clinical Neurology and Neurosurgery) Tj ETQq1 1 0.784314 rgBT /Overlock 1 2021, 208, 106820.	0.6	0
204	Dysexecutive Alzheimerâ€™s Disease with Lewy Body Disease Co-Pathology. Current Alzheimer Research, 2022, 19, 330-333.	0.7	0
205	Time in therapeutic range of anticoagulation among patients with atrial fibrillation and cerebral amyloid angiopathy. Baylor University Medical Center Proceedings, 2022, 35, 162-167.	0.2	0
206	Exercise and Brain Health. Neurology, 2022, 98, 825-826.	1.5	0
207	Author Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. Neurology, 2022, 98, 644-644.	1.5	0